Five an­a­lyt­ics firms launch RWE lob­by­ing group to press Con­gress, FDA on guid­ance, Cures 2.0

With around 75% of all new drug ap­provals in 2020 in­clud­ing re­al world ev­i­dence in their sub­mis­sions to FDA, da­ta and an­a­lyt­ics firms Ae­tion, Flat­iron Health (an in­de­pen­dent af­fil­i­ate of Roche), IQVIA, Syapse, and Tem­pus are gear­ing up to press Con­gress and the FDA even fur­ther on us­ing RWE to ac­cel­er­ate drug de­vel­op­ment.

The com­pa­nies all chipped in to hire the lob­by­ing firm Cov­ing­ton to run the new RWE Al­liance. Ken Tarkoff, CEO of Syapse, told End­points News in an in­ter­view that as the or­ga­ni­za­tion grows over time, the al­liance is hop­ing new com­pa­nies will pay to be mem­bers of the al­liance to fur­ther the cause.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.